Last reviewed · How we verify

Mycophenolate mofetil, Standard dose — Competitive Intelligence Brief

Mycophenolate mofetil, Standard dose (Mycophenolate mofetil, Standard dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inosine monophosphate dehydrogenase (IMPDH) inhibitor. Area: Immunology.

marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Mycophenolate mofetil, Standard dose (Mycophenolate mofetil, Standard dose) — Hoffmann-La Roche. Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mycophenolate mofetil, Standard dose TARGET Mycophenolate mofetil, Standard dose Hoffmann-La Roche marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II
sirolimus (drug), mmf (drug) sirolimus (drug), mmf (drug) University Hospital Muenster marketed Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination) mTOR (sirolimus); IMPDH type II (MMF)
Mycophenolate Mofetil (MMF) Mycophenolate Mofetil (MMF) ITB-Med LLC marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II
Mycophenolate Mofetil Cap./Tab. Mycophenolate Mofetil Cap./Tab. Chong Kun Dang Pharmaceutical marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant IMPDH type II (inosine monophosphate dehydrogenase)
Mycophenolate Na Mycophenolate Na Sanofi marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II
Myfortic Escalation Myfortic Escalation East Carolina University marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II
LCP-tacrolimus QD + MMF BID LCP-tacrolimus QD + MMF BID University Hospital, Limoges marketed Calcineurin inhibitor + antimetabolite combination Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inosine monophosphate dehydrogenase (IMPDH) inhibitor class)

  1. Hoffmann-La Roche · 2 drugs in this class
  2. East Carolina University · 1 drug in this class
  3. ITB-Med LLC · 1 drug in this class
  4. National Cancer Institute (NCI) · 1 drug in this class
  5. Sanofi · 1 drug in this class
  6. University Hospital, Limoges · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mycophenolate mofetil, Standard dose — Competitive Intelligence Brief. https://druglandscape.com/ci/mycophenolate-mofetil-standard-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: